The Experts below are selected from a list of 276 Experts worldwide ranked by ideXlab platform

Peter M Voorhees - One of the best experts on this subject based on the ideXlab platform.

Allison Kupsh - One of the best experts on this subject based on the ideXlab platform.

Anna Waszczukgajda - One of the best experts on this subject based on the ideXlab platform.

Justin Arnall - One of the best experts on this subject based on the ideXlab platform.

Niels W C J Van De Donk - One of the best experts on this subject based on the ideXlab platform.

  • Leptomeningeal metastases from primary Plasma Cell Leukemia
    Blood, 2013
    Co-Authors: Niels W C J Van De Donk, Henk M Lokhorst
    Abstract:

    ![Figure][1] Here, we describe a 52-year-old woman with a history of primary Plasma Cell Leukemia (PCL) who achieved complete remission after the tandem of autologous and nonmyeloablative allogeneic stem Cell transplantation (SCT). Nine months after the allogeneic SCT, she presented with

  • how i treat Plasma Cell Leukemia
    Blood, 2012
    Co-Authors: Niels W C J Van De Donk, Henk M Lokhorst, Kenneth C Anderson, Paul G Richardson
    Abstract:

    Primary Plasma Cell Leukemia (pPCL) is a rare and aggressive Plasma Cell proliferative disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory features. Compared with multiple myeloma, pPCL presents more often with extramedullary involvement, anemia, thrombocytopenia, hypercalcemia, elevated serum β2-microglobulin and lactate dehydrogenase levels, as well as impaired renal function. Many of the genetic aberrations observed in newly diagnosed pPCL are typically found in advanced multiple myeloma. These cytogenetic abnormalities and mutations lead to increased proliferation, enhanced inhibition of apoptosis, escape from immune surveillance, and independence from the BM microenvironment, with changes in expression of adhesion molecules or chemokine receptors. The outcome of pPCL has improved with the introduction of autologous stem Cell transplantation and combination approaches with novel agents, including bortezomib and immunomodulatory drugs, such as lenalidomide. In this review, we provide an overview of currently available therapeutic options with recommendations of how these treatment modalities can best be used to improve outcome for Plasma Cell Leukemia patients.